GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OTCPK:OSSUY) » Definitions » EV-to-EBITDA

Embla Medical hf (Embla Medical hf) EV-to-EBITDA : 15.76 (As of Apr. 28, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Embla Medical hf EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Embla Medical hf's enterprise value is $2,275.5 Mil. Embla Medical hf's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $144.4 Mil. Therefore, Embla Medical hf's EV-to-EBITDA for today is 15.76.

The historical rank and industry rank for Embla Medical hf's EV-to-EBITDA or its related term are showing as below:

OSSUY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.01   Med: 19.5   Max: 40.74
Current: 15.91

During the past 13 years, the highest EV-to-EBITDA of Embla Medical hf was 40.74. The lowest was 10.01. And the median was 19.50.

OSSUY's EV-to-EBITDA is ranked worse than
52.47% of 486 companies
in the Medical Devices & Instruments industry
Industry Median: 15.12 vs OSSUY: 15.91

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), Embla Medical hf's stock price is $4.50. Embla Medical hf's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.135. Therefore, Embla Medical hf's PE Ratio for today is 33.33.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Embla Medical hf EV-to-EBITDA Historical Data

The historical data trend for Embla Medical hf's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embla Medical hf EV-to-EBITDA Chart

Embla Medical hf Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.25 42.86 20.83 20.66 14.50

Embla Medical hf Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.78 18.60 15.62 14.50 17.73

Competitive Comparison of Embla Medical hf's EV-to-EBITDA

For the Medical Devices subindustry, Embla Medical hf's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's EV-to-EBITDA falls into.



Embla Medical hf EV-to-EBITDA Calculation

Embla Medical hf's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2275.502/144.35
=15.76

Embla Medical hf's current Enterprise Value is $2,275.5 Mil.
Embla Medical hf's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $144.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embla Medical hf  (OTCPK:OSSUY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Embla Medical hf's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.50/0.135
=33.33

Embla Medical hf's share price for today is $4.50.
Embla Medical hf's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.135.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Embla Medical hf EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Embla Medical hf's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Embla Medical hf (Embla Medical hf) Business Description

Traded in Other Exchanges
Address
Grjothals 5, Reykjavik, ISL
Ossur hf is engaged in the design, development, manufacture, and sale of prosthetics and bracing & support products. The company's products improve mobility through technologies in the field of braces, supports, prosthetic limbs, and compression therapy. Its segments are the Bracing & Supports and Prosthetics segment. The bracing & support products are used to support joints and other body parts for therapeutic and preventative purposes. The Prosthetics segment includes artificial limbs and related products for individuals born without limbs. Its geographical segments are the Americas; Europe, the Middle East & Africa (EMEA); and the Americas & Asia-Pacific (APAC), of which the Americas generate nearly half of the company's revenue.